Review



self complementary aav vector  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc self complementary aav vector
    Dp427 restoration 9 weeks after bilateral ICV injection of AAV9-U7-51M (A) Schematic representation of the U7snRNA and its target site on dystrophin pre-mRNA. (B) Structure of the <t>AAV</t> <t>vector</t> encoding the U7snRNA cassette. The cassette is flanked by inverted terminal repeats (ITRs) and includes an engineered U7snRNA sequence (gray box) with an antisense region, driven by its natural U7 promoter (hatched box) and 3′ downstream elements (white box). (C) Overview of the experimental procedure. (D) Left: RT-PCR gel showing exon 51 skipping 9 weeks post-injection. SM: DNA ladder; Mouse 0: mdx52 mouse injected with U7-Scramble (negative control); Mice 1–7: mdx52 mice treated with a low dose of AAV9-U7-51M (1E11 vg); Mice 8–15: mdx52 mice treated with a high dose of AAV9-U7-51M (1E12 vg). Right: Quantification of exon 51 skipping via RT-qPCR, comparing low- and high-dose treatments ( n = 7 for low dose in orange and 8 for high dose in red). (E) Quantification of Dp427 protein restoration by western blot after AAV9-U7-51M injection at low and high doses expressed in a percentage of the WT ( n = 7 for low dose in orange and 8 for high dose in red). Statistical analysis (two-way ANOVA) did not reveal a dose-dependent effect due to high interindividual variability. (F) Combined analysis of Dp427 protein rescue levels irrespective of the injected dose expressed in a percentage of the WT ( n = 15) in the three brain structures.
    Self Complementary Aav Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 31 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/self complementary aav vector/product/Addgene inc
    Average 93 stars, based on 31 article reviews
    self complementary aav vector - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Ineffective behavioral rescue despite partial brain Dp427 restoration by AAV9-U7-mediated exon 51 skipping in mdx52 mice"

    Article Title: Ineffective behavioral rescue despite partial brain Dp427 restoration by AAV9-U7-mediated exon 51 skipping in mdx52 mice

    Journal: Molecular Therapy. Nucleic Acids

    doi: 10.1016/j.omtn.2025.102779

    Dp427 restoration 9 weeks after bilateral ICV injection of AAV9-U7-51M (A) Schematic representation of the U7snRNA and its target site on dystrophin pre-mRNA. (B) Structure of the AAV vector encoding the U7snRNA cassette. The cassette is flanked by inverted terminal repeats (ITRs) and includes an engineered U7snRNA sequence (gray box) with an antisense region, driven by its natural U7 promoter (hatched box) and 3′ downstream elements (white box). (C) Overview of the experimental procedure. (D) Left: RT-PCR gel showing exon 51 skipping 9 weeks post-injection. SM: DNA ladder; Mouse 0: mdx52 mouse injected with U7-Scramble (negative control); Mice 1–7: mdx52 mice treated with a low dose of AAV9-U7-51M (1E11 vg); Mice 8–15: mdx52 mice treated with a high dose of AAV9-U7-51M (1E12 vg). Right: Quantification of exon 51 skipping via RT-qPCR, comparing low- and high-dose treatments ( n = 7 for low dose in orange and 8 for high dose in red). (E) Quantification of Dp427 protein restoration by western blot after AAV9-U7-51M injection at low and high doses expressed in a percentage of the WT ( n = 7 for low dose in orange and 8 for high dose in red). Statistical analysis (two-way ANOVA) did not reveal a dose-dependent effect due to high interindividual variability. (F) Combined analysis of Dp427 protein rescue levels irrespective of the injected dose expressed in a percentage of the WT ( n = 15) in the three brain structures.
    Figure Legend Snippet: Dp427 restoration 9 weeks after bilateral ICV injection of AAV9-U7-51M (A) Schematic representation of the U7snRNA and its target site on dystrophin pre-mRNA. (B) Structure of the AAV vector encoding the U7snRNA cassette. The cassette is flanked by inverted terminal repeats (ITRs) and includes an engineered U7snRNA sequence (gray box) with an antisense region, driven by its natural U7 promoter (hatched box) and 3′ downstream elements (white box). (C) Overview of the experimental procedure. (D) Left: RT-PCR gel showing exon 51 skipping 9 weeks post-injection. SM: DNA ladder; Mouse 0: mdx52 mouse injected with U7-Scramble (negative control); Mice 1–7: mdx52 mice treated with a low dose of AAV9-U7-51M (1E11 vg); Mice 8–15: mdx52 mice treated with a high dose of AAV9-U7-51M (1E12 vg). Right: Quantification of exon 51 skipping via RT-qPCR, comparing low- and high-dose treatments ( n = 7 for low dose in orange and 8 for high dose in red). (E) Quantification of Dp427 protein restoration by western blot after AAV9-U7-51M injection at low and high doses expressed in a percentage of the WT ( n = 7 for low dose in orange and 8 for high dose in red). Statistical analysis (two-way ANOVA) did not reveal a dose-dependent effect due to high interindividual variability. (F) Combined analysis of Dp427 protein rescue levels irrespective of the injected dose expressed in a percentage of the WT ( n = 15) in the three brain structures.

    Techniques Used: Injection, Plasmid Preparation, Sequencing, Reverse Transcription Polymerase Chain Reaction, Negative Control, Quantitative RT-PCR, Western Blot



    Similar Products

    93
    Addgene inc self complementary aav vector
    Dp427 restoration 9 weeks after bilateral ICV injection of AAV9-U7-51M (A) Schematic representation of the U7snRNA and its target site on dystrophin pre-mRNA. (B) Structure of the <t>AAV</t> <t>vector</t> encoding the U7snRNA cassette. The cassette is flanked by inverted terminal repeats (ITRs) and includes an engineered U7snRNA sequence (gray box) with an antisense region, driven by its natural U7 promoter (hatched box) and 3′ downstream elements (white box). (C) Overview of the experimental procedure. (D) Left: RT-PCR gel showing exon 51 skipping 9 weeks post-injection. SM: DNA ladder; Mouse 0: mdx52 mouse injected with U7-Scramble (negative control); Mice 1–7: mdx52 mice treated with a low dose of AAV9-U7-51M (1E11 vg); Mice 8–15: mdx52 mice treated with a high dose of AAV9-U7-51M (1E12 vg). Right: Quantification of exon 51 skipping via RT-qPCR, comparing low- and high-dose treatments ( n = 7 for low dose in orange and 8 for high dose in red). (E) Quantification of Dp427 protein restoration by western blot after AAV9-U7-51M injection at low and high doses expressed in a percentage of the WT ( n = 7 for low dose in orange and 8 for high dose in red). Statistical analysis (two-way ANOVA) did not reveal a dose-dependent effect due to high interindividual variability. (F) Combined analysis of Dp427 protein rescue levels irrespective of the injected dose expressed in a percentage of the WT ( n = 15) in the three brain structures.
    Self Complementary Aav Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/self complementary aav vector/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    self complementary aav vector - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    95
    Addgene inc self complementary aav scaav vectors
    Increased long-term specificity and efficiency for the minimal hIBA1a promoter when packaged in <t>scAAV</t> (A) Schematic diagram of the experimental procedure. scAAV5 virus with the hIBA1a promoter was injected into sham mice or mice with L-NIO-induced stroke. Brains were analyzed 1 week or 4 weeks later. (B) Representative confocal images showing marker expression for the indicated conditions. Scale bars, 50 μm. (C) Quantifications showing microglia-specificity of GFP expression for the indicated conditions (mean ± SEM; n = 3 mice per group). (D) Quantifications showing microglia transduction efficiency for the indicated conditions (mean ± SEM; n = 3 mice per group).
    Self Complementary Aav Scaav Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/self complementary aav scaav vectors/product/Addgene inc
    Average 95 stars, based on 1 article reviews
    self complementary aav scaav vectors - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    90
    Sanofi self-complementary aav (scaav) vectors
    Increased long-term specificity and efficiency for the minimal hIBA1a promoter when packaged in <t>scAAV</t> (A) Schematic diagram of the experimental procedure. scAAV5 virus with the hIBA1a promoter was injected into sham mice or mice with L-NIO-induced stroke. Brains were analyzed 1 week or 4 weeks later. (B) Representative confocal images showing marker expression for the indicated conditions. Scale bars, 50 μm. (C) Quantifications showing microglia-specificity of GFP expression for the indicated conditions (mean ± SEM; n = 3 mice per group). (D) Quantifications showing microglia transduction efficiency for the indicated conditions (mean ± SEM; n = 3 mice per group).
    Self Complementary Aav (Scaav) Vectors, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/self-complementary aav (scaav) vectors/product/Sanofi
    Average 90 stars, based on 1 article reviews
    self-complementary aav (scaav) vectors - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Biopharm GmbH self-complementary (sc) aav vectors
    Increased long-term specificity and efficiency for the minimal hIBA1a promoter when packaged in <t>scAAV</t> (A) Schematic diagram of the experimental procedure. scAAV5 virus with the hIBA1a promoter was injected into sham mice or mice with L-NIO-induced stroke. Brains were analyzed 1 week or 4 weeks later. (B) Representative confocal images showing marker expression for the indicated conditions. Scale bars, 50 μm. (C) Quantifications showing microglia-specificity of GFP expression for the indicated conditions (mean ± SEM; n = 3 mice per group). (D) Quantifications showing microglia transduction efficiency for the indicated conditions (mean ± SEM; n = 3 mice per group).
    Self Complementary (Sc) Aav Vectors, supplied by Biopharm GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/self-complementary (sc) aav vectors/product/Biopharm GmbH
    Average 90 stars, based on 1 article reviews
    self-complementary (sc) aav vectors - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    Dp427 restoration 9 weeks after bilateral ICV injection of AAV9-U7-51M (A) Schematic representation of the U7snRNA and its target site on dystrophin pre-mRNA. (B) Structure of the AAV vector encoding the U7snRNA cassette. The cassette is flanked by inverted terminal repeats (ITRs) and includes an engineered U7snRNA sequence (gray box) with an antisense region, driven by its natural U7 promoter (hatched box) and 3′ downstream elements (white box). (C) Overview of the experimental procedure. (D) Left: RT-PCR gel showing exon 51 skipping 9 weeks post-injection. SM: DNA ladder; Mouse 0: mdx52 mouse injected with U7-Scramble (negative control); Mice 1–7: mdx52 mice treated with a low dose of AAV9-U7-51M (1E11 vg); Mice 8–15: mdx52 mice treated with a high dose of AAV9-U7-51M (1E12 vg). Right: Quantification of exon 51 skipping via RT-qPCR, comparing low- and high-dose treatments ( n = 7 for low dose in orange and 8 for high dose in red). (E) Quantification of Dp427 protein restoration by western blot after AAV9-U7-51M injection at low and high doses expressed in a percentage of the WT ( n = 7 for low dose in orange and 8 for high dose in red). Statistical analysis (two-way ANOVA) did not reveal a dose-dependent effect due to high interindividual variability. (F) Combined analysis of Dp427 protein rescue levels irrespective of the injected dose expressed in a percentage of the WT ( n = 15) in the three brain structures.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Ineffective behavioral rescue despite partial brain Dp427 restoration by AAV9-U7-mediated exon 51 skipping in mdx52 mice

    doi: 10.1016/j.omtn.2025.102779

    Figure Lengend Snippet: Dp427 restoration 9 weeks after bilateral ICV injection of AAV9-U7-51M (A) Schematic representation of the U7snRNA and its target site on dystrophin pre-mRNA. (B) Structure of the AAV vector encoding the U7snRNA cassette. The cassette is flanked by inverted terminal repeats (ITRs) and includes an engineered U7snRNA sequence (gray box) with an antisense region, driven by its natural U7 promoter (hatched box) and 3′ downstream elements (white box). (C) Overview of the experimental procedure. (D) Left: RT-PCR gel showing exon 51 skipping 9 weeks post-injection. SM: DNA ladder; Mouse 0: mdx52 mouse injected with U7-Scramble (negative control); Mice 1–7: mdx52 mice treated with a low dose of AAV9-U7-51M (1E11 vg); Mice 8–15: mdx52 mice treated with a high dose of AAV9-U7-51M (1E12 vg). Right: Quantification of exon 51 skipping via RT-qPCR, comparing low- and high-dose treatments ( n = 7 for low dose in orange and 8 for high dose in red). (E) Quantification of Dp427 protein restoration by western blot after AAV9-U7-51M injection at low and high doses expressed in a percentage of the WT ( n = 7 for low dose in orange and 8 for high dose in red). Statistical analysis (two-way ANOVA) did not reveal a dose-dependent effect due to high interindividual variability. (F) Combined analysis of Dp427 protein rescue levels irrespective of the injected dose expressed in a percentage of the WT ( n = 15) in the three brain structures.

    Article Snippet: The resulting U7snRNA fragments were cloned between the inverted terminal repeats (ITRs) of a self-complementary AAV vector (pscAAV, Addgene plasmid #83279; gift from Mark Kay) for subsequent AAV production.

    Techniques: Injection, Plasmid Preparation, Sequencing, Reverse Transcription Polymerase Chain Reaction, Negative Control, Quantitative RT-PCR, Western Blot

    Increased long-term specificity and efficiency for the minimal hIBA1a promoter when packaged in scAAV (A) Schematic diagram of the experimental procedure. scAAV5 virus with the hIBA1a promoter was injected into sham mice or mice with L-NIO-induced stroke. Brains were analyzed 1 week or 4 weeks later. (B) Representative confocal images showing marker expression for the indicated conditions. Scale bars, 50 μm. (C) Quantifications showing microglia-specificity of GFP expression for the indicated conditions (mean ± SEM; n = 3 mice per group). (D) Quantifications showing microglia transduction efficiency for the indicated conditions (mean ± SEM; n = 3 mice per group).

    Journal: iScience

    Article Title: Simple and highly specific targeting of resident microglia with adeno-associated virus

    doi: 10.1016/j.isci.2024.110706

    Figure Lengend Snippet: Increased long-term specificity and efficiency for the minimal hIBA1a promoter when packaged in scAAV (A) Schematic diagram of the experimental procedure. scAAV5 virus with the hIBA1a promoter was injected into sham mice or mice with L-NIO-induced stroke. Brains were analyzed 1 week or 4 weeks later. (B) Representative confocal images showing marker expression for the indicated conditions. Scale bars, 50 μm. (C) Quantifications showing microglia-specificity of GFP expression for the indicated conditions (mean ± SEM; n = 3 mice per group). (D) Quantifications showing microglia transduction efficiency for the indicated conditions (mean ± SEM; n = 3 mice per group).

    Article Snippet: The self-complementary AAV (scAAV) vectors were based on the scAAV-CAG-GFP vector (Addgene #83279) by replacing the CAG promoter with the hIBA1 promoter.

    Techniques: Virus, Injection, Marker, Expressing, Transduction

    Journal: iScience

    Article Title: Simple and highly specific targeting of resident microglia with adeno-associated virus

    doi: 10.1016/j.isci.2024.110706

    Figure Lengend Snippet:

    Article Snippet: The self-complementary AAV (scAAV) vectors were based on the scAAV-CAG-GFP vector (Addgene #83279) by replacing the CAG promoter with the hIBA1 promoter.

    Techniques: Recombinant, Software